Literature DB >> 20553090

Atorvastatin: safety and tolerability.

Vasilios G Athyros1, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P Mikhailidis.   

Abstract

IMPORTANCE OF THE FIELD: Atorvastatin is the most widely used statin administered in a variety of settings, including primary and secondary prevention of cardiovascular events, in the elderly, in patients with chronic kidney disease and in diabetic patients. Therefore, the safety and tolerability of atorvastatin is of paramount importance. AREAS COVERED IN THIS REVIEW: We searched MEDLINE for literature published between 1997 and 2010 on the safety and tolerability of atorvastatin. We retrieved data from randomized controlled trials, meta-analyses, post-marketing studies, reports to regulatory bodies and case reports of rare adverse events. WHAT THE READER WILL GAIN: The reader will gain insight into the incidence, severity, prevention and management of the major adverse effects of atorvastatin (i.e., liver function abnormalities and muscle-related side effects) overall and in special populations. TAKE HOME MESSAGE: The existing data suggest that atorvastatin is generally well tolerated across the range of its therapeutic dosage (10 - 80 mg/day).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553090     DOI: 10.1517/14740338.2010.495385

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  16 in total

1.  Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Authors:  Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

Review 2.  Lipid-lowering agents in the management of nonalcoholic fatty liver disease.

Authors:  Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2014-10-27

3.  Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.

Authors:  Beata Banaszewska; Leszek Pawelczyk; Robert Z Spaczynski; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

Review 4.  Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants.

Authors:  Haixia Li; Cailian Wang; Shuo Zhang; Sihao Sun; Ruifei Li; Meijuan Zou; Gang Cheng
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

5.  Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin.

Authors:  Mo Zhou; Jinkai Zheng; Jinfeng Bi; Xinye Wu; Jian Lyu; Kun Gao
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

Review 6.  Safety of statins: an update.

Authors:  Miao Hu; Bernard M Y Cheung; Brian Tomlinson
Journal:  Ther Adv Drug Saf       Date:  2012-06

Review 7.  The gut microbiota and human health with an emphasis on the use of microencapsulated bacterial cells.

Authors:  Satya Prakash; Catherine Tomaro-Duchesneau; Shyamali Saha; Arielle Cantor
Journal:  J Biomed Biotechnol       Date:  2011-07-02

8.  Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression.

Authors:  Ran Li; Ye-Hua Gan
Journal:  Int J Mol Sci       Date:  2017-05-08       Impact factor: 5.923

9.  Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study.

Authors:  Abdullah K Altwairgi; Waleed A Alghareeb; Fouad H AlNajjar; Hussain Alhussain; Eyad Alsaeed; Ali Abdullah O Balbaid; Sadeq Aldanan; Yasser Orz; Abdullah A Alsharm
Journal:  Invest New Drugs       Date:  2020-08-27       Impact factor: 3.850

10.  Atorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.